Prostate Cancer | Specialty

Expert Discusses QOL at 2 Years Following Prostate Cancer Treatment

August 10th 2017

Andrew Stephenson, MD, discusses the impact of various approaches—radiation, surgery, and active surveillance—on patients’ quality of life 2 years following treatment.

Early Chemo Linked to Improved PFS in High-Volume Metastatic Prostate Cancer

August 10th 2017

Patients with high-volume, castration-naïve metastatic prostate cancer may have superior progression-free survival outcomes when treated with early docetaxel.

Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

August 10th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Dr. Stephenson on Advancements of Treatment for Prostate Cancer

August 10th 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses advancements being made in the field of prostate cancer.

Dr. Feldman on Managing Patients With Prostate Cancer Under Active Surveillance

August 9th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses managing patients with prostate cancer under active surveillance.

Dr. Choi on Considering Factors for RT in Prostate Cancer

August 7th 2017

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.

Using Population Science to Fill in the Blanks

August 7th 2017

When it comes to treating older populations for cancer, it’s often the case that the only available data are based on trials of younger patients in far healthier condition.

Genomic Landscape of Prostate Cancer Aligns With Breast Cancer Subtypes

August 4th 2017

A comparison of the genomic risk profiles of patients with low-risk prostate cancer who are candidates for active surveillance against higher-risk patients, discovered that substantial genomic heterogeneity exists among patients with prostate cancer.

Dr. Yu Compares Treatment Options for Prostate Cancer

August 4th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

Dr. Choyke on Which Patients Benefit From Active Surveillance in Prostate Cancer

August 3rd 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

Experts Explain Impact of LATITUDE Abiraterone Data in Prostate Cancer

August 3rd 2017

Jorge Garcia, MD, and Kim Chi, MD, share their insights on the LATITUDE trial in prostate cancer.

Dr. Feldman on Challenges Facing the Development of Biomarkers for Prostate Cancer

August 3rd 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.

Dr. Chi on Abiraterone Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

August 1st 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses a study investigating abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Agarwal on Candidates for Docetaxel Versus Abiraterone and Prednisone

August 1st 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses how to determine which patient with prostate cancer is a candidate for docetaxel versus abiraterone acetate (Zytiga) and prednisone.

Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

July 31st 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

Prostate Cancer: Advice for Oncologists on AR-V7 Testing

July 31st 2017

Experimental Strategies for AR-V7+ CRPC

July 31st 2017

Precision Medicine in mCRPC

July 31st 2017

Recent AR-V7 Data in Prostate Cancer

July 31st 2017

Prostate Cancer: Educating Physicians About AR-V7 Testing

July 31st 2017